Adzynma 1500IU INJ, lyphl
Ended Awarded Last action
- Contract number
- 36C26025F0047
- Awardee
-
Takeda Pharmaceuticals America, Inc. UEI DDEVYUAXJ624 Part of Takeda Pharmaceutical Company LIMITED
- Awarding agency
-
Veterans Integrated Service Network 20
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $48,569
Award facts
- Contract value 100% obligated
- $48,568.50 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Dublin, OH 43017, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | -$1,632 | |
| Original award | $50,200 |
About this award
Takeda Pharmaceuticals America Inc., a subsidiary of Japan-based Takeda Pharmaceutical Company Limited, received a $48.6K delivery order from Veterans Integrated Service Network 20 (VISN 20) on October 3, 2024, for the supply of ADZYNMA 1500IU injectable lyophilized medication. The award is structured as a firm fixed-price delivery order under the GSA Pharmaceuticals and Drugs Schedule (FSS-61-IB) with no set-aside designation, reflecting the specialized and limited-source nature of the pharmaceutical product. Performance is scheduled to be completed by January 3, 2025, at a facility located in Dublin, Ohio.
This delivery order draws from Takeda Pharmaceuticals America's broader Blanket Purchase Agreement with the VA National Acquisition Center, valued at $131M and effective through July 2026. ADZYNMA is used in the treatment of hereditary angioedema, a rare genetic disorder, and aligns with the VA's commitment to providing advanced therapeutic options for veteran patients. The contract reflects Takeda's established role as a critical supplier of specialty pharmaceuticals to federal healthcare systems, particularly for rare disease treatments and other complex medical conditions requiring specialized pharmaceutical expertise.
Quick answers
Who was awarded contract 36C26025F0047?
36C26025F0047 was awarded to Takeda Pharmaceuticals America, Inc. by Veterans Integrated Service Network 20 (Veterans Health Administration) on October 3, 2024.
How much is contract 36C26025F0047 worth?
The government has obligated $48,569 on 36C26025F0047.
Is contract 36C26025F0047 an order under another contract?
Yes. 36C26025F0047 is a delivery order under V797D50492, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C26025F0047 competed?
The extent of competition for 36C26025F0047 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award